Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Catabasis Pharmaceuticals Clear all
Completed Phase 3 Interventional Results available

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03703882
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Edasalonexent, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers

NCT01440166
View directory record Official record
Conditions
Healthy
Interventions
Drug, Placebo
Drug · Other
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

NCT02374047
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
CAT-2054, Placebo, CAT-2054-C, Atorvastatin
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

NCT02608697
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
CAT-2054, Placebo, Atorvastatin
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
34
States / cities
Muscle Shoals, Alabama • Huntington Park, California • Lomita, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of CAT-1004 Biomarkers in Healthy Subjects

NCT01670773
View directory record Official record
Conditions
Assessment of Mechanistic Blood Biomarkers in Healthy Humans
Interventions
CAT-1004, Salsalate + DHA, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy

NCT02439216
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Edasalonexent, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Sep 30, 2026, 5:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families

NCT03680365
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Burden, Dependency, Disability Physical, Disease Management, Impairment, Rare Diseases
Interventions
Not listed
Lead sponsor
Jett Foundation, Inc.
Other
Eligibility
11 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia

NCT01912560
View directory record Official record
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
CAT-2003, Placebo, Statin
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Muscle Shoals, Alabama • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 30, 2026, 5:42 PM EDT
Terminated Phase 3 Interventional

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03917719
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Edasalonexent
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 12 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Sacramento, California • Atlanta, Georgia • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects

NCT04543370
View directory record Official record
Conditions
Healthy
Interventions
Edasalonexent 2000 mg TID, Midazolam 2 MG/ML, Deflazacort 36Mg Tab
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

NCT01968720
View directory record Official record
Conditions
Hyperlipidemias, Hypertriglyceridemia, Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases
Interventions
CAT-2003, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Miami, Florida • Indianapolis, Indiana • Auburn, Maine + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2015 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes

NCT01511900
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
CAT 1004, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Sep 30, 2026, 5:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003

NCT01725594
View directory record Official record
Conditions
Dyslipidemia
Interventions
CAT 2003, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Sep 30, 2026, 5:42 PM EDT